




- How (antimicrobial) drugs reach the brain?

- **Blood-brain barrier** (which is composed of non-fenestrated capillary endothelium + astrocyte sheath) has tight junctions which will not allow all molecules to cross from blood to the brain
- **Blood-CSF barrier** (which is composed of fenestrated capillary endothelium + ependymal cells of choroid plexus)
- **Generally, drugs are usually given intravenously or orally (and sometimes intrathecally: used less frequently nowadays).**
  - ✓ Intrathecally-administered drugs are directly introduced to ventricles (as a result the drug will get into the cerebrospinal fluid CSF).
  - ✓ Intravenously administered drugs (most common in case of meningitis): they get into venous blood → entering systemic circulation → and eventually reaching arterial blood supply of the brain → from there, there are 2 possible pathways for the drug:

- ❖ *Either entering extracellular fluid compartment of the brain through blood-brain barrier.*
- ❖ *Or entering cerebrospinal fluid compartment through blood-CSF barrier.*

**Note:** drugs can move between extracellular fluid and CSF through brain-CSF barrier and depending on concentration gradient. Drug will also diffuse from between extracellular fluid and intracellular fluid compartment of brain cells.



- Factors influencing passage of drugs from blood into brain/CSF:

- **Molecular weight:** small molecules pass more easily than large molecules. Fortunately, most of antimicrobial drugs are low-molecular drugs.
- **Protein binding:** greater the protein binding inverses the relation of how effectively a molecule can get across the blood-brain barrier.
- **Lipid/water partition coefficient (lipid solubility):** greater is the lipid solubility the more easier for the molecule to get across the blood-brain barrier.
- **pKa (ionization constant):** greater is the unionized form → more lipid solubility.
- **Status of meninges:** whenever there is meningeal inflammation, even those drugs with modest permeability can have a good therapeutic effect. At birth, blood-brain barrier is not fully functional (it takes several weeks to reach the adult level of maturation) → thus a newborn baby will have increased permeability of the meninges.



- **Principles of treatment in meningitis:**

- **Blood and CSF samples are obtained before starting treatment.**
- **In acute meningitis, antibiotics are almost always given intravenously (IV).** An exception is tuberculosis in which treatment is orally
- **After patient becomes afebrile, treatment is recommended to be continued for 1 week.**
  - ✓ In pneumococcal meningitis: it is continued for 2 weeks.
  - ✓ In gram-negative infections: it is continued for 3 weeks.
- **General management of complications:**
  - ✓ Maintaining fluid balance, prevention of aspiration and maintenance of patent airway.
  - ✓ Treatment of convulsion (using anti-convulsants with least effect in producing respiratory depression). Example: lorazepam.
  - ✓ Treatment of cerebral edema (which results from inflammatory process): by giving mannitol and corticosteroids (especially dexamethasone).
  - ✓ Treatment of headache: by analgesics.

- **Therapeutic issues pertinent to drug management of meningitis:**

- Passage of antimicrobials is increased with presence of meningeal inflammation (inflammation increases permeability of antimicrobials such as penicillin).
- Concomitant (المصاحب) steroid therapy can alter passage of certain antimicrobials (such as penicillins and aminoglycosides) across the blood-brain barrier.
- **Antimicrobial(s) choice is based on antimicrobial spectrum and the ability of antimicrobial to achieve sufficient concentration in the brain/CSF:**
  - ❖ Very good: metronidazole (very useful to treat brain abscess because it is achieving much higher concentration in the abscess than in blood).
  - ❖ Good: penicillins and cephalosporins (recommendations for meningitis are limited with 3<sup>rd</sup> generation cephalosporins).
  - ❖ Fair/poor: aminoglycosides, clindamycin, macrolides (azithromycin is the only macrolide which is used for meningitis) and vancomycin (has an important role especially in empiric therapy of meningitis).

- **Empiric therapy for bacterial meningitis:**

<u>Age group/predisposition</u>	<u>Recommended therapy</u>
Neonate (up to 2 months of age)	Ampicillin + cefotaxime
Infants and children (2-5 years)	Cefotaxime + vancomycin
Older children and adults	Cefotaxime + vancomycin
Elderly (+50 years)	Cefotaxime + vancomycin
Post-neurosurgical procedure	Ceftazidime + vancomycin
Closed head trauma	Cefotaxime + vancomycin
Open head trauma	Ceftazidime + vancomycin

- **Definitive therapy for bacterial meningitis:**

<u>Pathogen</u>	<u>Recommended treatment</u>
<b>H.influenzae:</b> <ul style="list-style-type: none"> <li>• <math>\beta</math>-lactamase negative</li> <li>• <math>\beta</math>-lactamase positive</li> </ul>	Ampicillin Cefotaxime
<b>N.meningitidis:</b> <ul style="list-style-type: none"> <li>• Penicillin-sensitive</li> <li>• Penicillin-resistant</li> </ul>	Penicillin G or ampicillin Cefotaxime
<b>Strep.pneumoniae:</b> <ul style="list-style-type: none"> <li>• Penicillin-sensitive</li> <li>• Penicillin-resistant</li> </ul>	Penicillin G or ampicillin Cefotaxime + vancomycin
<b>Strep.agalactiae</b>	Penicillin G/ampicillin + gentamycin
<b>L.monocytogenes</b>	Penicillin G/ampicillin $\pm$ gentamycin
<b>Enterobacteriaceae</b>	



<ul style="list-style-type: none"> <li>• E.coli, Klebsiella</li> <li>• Enterobacter, serratia</li> </ul>	Cefotaxime Cefepime
<b>P.aeruginosa</b>	Cefepime
<b>S.aureus:</b> <ul style="list-style-type: none"> <li>• MSSA</li> <li>• MRSA</li> </ul>	Naficillin or oxacillin. Vancomycin ± rifampin
<b>Staph.epidermidis</b>	Vancomycin ± rifampin

- **Corticosteroid (dexamethasone) therapy in meningitis:**

<u>Age groups</u>	<u>Causative organisms</u>	<u>Outcomes</u>
<b>Infants/children</b>	S.pneumoniae	Controversial
<b>Children</b>	H.influenzae	Decrease neurologic sequelae especially hearing loss
<b>Adolescents/adults</b>	Mycobacterium tuberculosis	Improves survival but not severe disability
<b>Adults</b>	S.pneumoniae	Better outcome
<b>All age groups</b>	N.meningitidis, fungi and viruses	No evidence supports a decrease in neurologic sequelae.

• **Note: rationale against corticosteroid use:**

- ✓ Decreased passage of some antimicrobials across blood-brain barrier.
- ✓ Increased incidence of GI-bleeding.

- **Prevention of meningitis (chemoprophylaxis):**

- **Patients with CSF-rhinorrhea or CSF-otorrhea:** oral penicillin-V (500mg till leak stops).
- **Close contacts of meningococcal meningitis:** rifampin 600mg for 2 days.
- **Pregnant women (in whom rifampin is contraindicated) and children:** ceftriaxone.

- **Tuberculous meningitis:**

- **Isoniazide, rifampicin, pyrazinamide and ethambutol → for 2 months.**
- **Followed by: isoniazide + rifampin → for 10 months.**

Note: prednisone (it is a prodrug which is hydroxylated to prednisolone in the liver) may be required in tuberculous meningitis if there is:

- ✓ *Spinal block.*
- ✓ *Raised intracranial pressure.*
- ✓ *Neurological signs.*
- ✓ *High CSF protein levels.*

- **Herpes encephalitis: intravenous acyclovir (for 10 days).**